An Excellent Investment in the Biotech Space?

Solid financial position
The company has a strong balance sheet with cash balance of $131.8 million as of last quarter. However, the company is still not profitable, as most of its funds are utilized in R&D and marketing expenses. The net loss during the second quarter of this year was $62.2 million, or $0.34 per share. The addition of Comeriq’s sales has already improved overall revenue, but the company still needs time to reach profitability.

Conclusion
Exelixis has a number of positives going for it to make it worth a second look. It has a solid product in a niche area where there’s hardly any focused competition and a robust pipeline. All of these factors put together make Exelixis a very interesting company for potential investors.

The article An Excellent Investment in the Biotech Space? originally appeared on Fool.com.

Kanak Kanti De has no position in any stocks mentioned. The Motley Fool recommends Exelixis. The Motley Fool owns shares of Exelixis. 

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.